World’s first Intranasal Vaccine iNCOVACC has recently received approval for Covid booster doses from Drugs Controller General of India (DCGI).
About:
It is developed by Bharat Biotech International Limited.
It was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.
The approval is under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein.
It is the world's first intranasal vaccine to receive both primary series and heterologous booster approval.
The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.
It is stable at 2-8 degrees Celsius for easy storage and distribution.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
